OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 99-114
Open Access | Times Cited: 6
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 99-114
Open Access | Times Cited: 6
Showing 6 citing articles:
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Sarah E. Thomas, Liana Barenbrug, Gerjon Hannink, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 565-578
Open Access | Times Cited: 14
Sarah E. Thomas, Liana Barenbrug, Gerjon Hannink, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 565-578
Open Access | Times Cited: 14
Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 5
Closed Access | Times Cited: 3
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 5
Closed Access | Times Cited: 3
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
Chang‐Yu Hsieh, Francis Li‐Tien Hsu, Tsen‐Fang Tsai
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2607-2620
Open Access | Times Cited: 1
Chang‐Yu Hsieh, Francis Li‐Tien Hsu, Tsen‐Fang Tsai
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2607-2620
Open Access | Times Cited: 1
Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study
Nicoletta Bernardini, Annunziata Dattola, Raimondo Rossi, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 12, pp. 1169-1169
Open Access | Times Cited: 1
Nicoletta Bernardini, Annunziata Dattola, Raimondo Rossi, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 12, pp. 1169-1169
Open Access | Times Cited: 1
Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021
Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, et al.
JEADV Clinical Practice (2024) Vol. 3, Iss. 5, pp. 1537-1547
Open Access
Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, et al.
JEADV Clinical Practice (2024) Vol. 3, Iss. 5, pp. 1537-1547
Open Access
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 12, pp. 3273-3290
Open Access
Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 12, pp. 3273-3290
Open Access
